ice-cold saline with a previously chilled mortar and pestle so as to make a 20 per cent homogenate. This was centrifuged in a Servall centrifuge at 1400 g for 15 minutes in the cold room. The supernatant fluid was then centrifuged at 7000 g for 10 minutes and the final supernatant fluid filtered through a chilled Selas 02 porosity filter candle under vacuum pressure. The extracts were either used immediately or sealed in 2 ml. glass ampoules and stored at -790 C. The extracts were prepared from thymus, spleen and lymph nodes of mice with either spontaneous or induced leukaemias: the spontaneous leukaemias were obtained from our own colony of Aki and from AKR mice received from other laboratories; the induced leukaemias were obtained from C3Hf/Gs mice inoculated by Dr. Gross with his potent Passage A filtrate (Gross, 1957b) .
Inoculation procedures.-Filtrates were generally injected into newborn mice less than 16 hours after birth, each baby mouse receiving 041 ml. by the intraperitoneal route, the needle first traversing the thigh muscles to avoid leakage. When Passage A filtrate was used however, suckling mice up to 14 days of age were injected, the volume of the inoculum being varied according to age: at 1 and 2 days 0-1 ml. was given, at 3 and 4 days 0-2 ml. and at 5 to 14 days 0-3 ml. Adult mice inoculated with filtrates received 0.5 ml. intraperitoneally daily for 3 days. Control mice were usually littermates identified by tail-clipping; they received either saline of filtrates heated to 56°C. for 30 minutes.
Transplantation of leukaemias.-For transplantation of leukaemias, cell suspensions were prepared from fresh leukaemic spleen by teasing out with forceps in a dish of saline. The cells were washed in saline to the desired volume so that 0 5 ml. of the suspension contained 30 to 50 million cells. This amount was injected intraperitoneally into adult mice of the strains tested for transplantability. The cells of each case of leukaemia to be transplanted were injected into 3 to 5 mice of each strain.
Induction of immune tolerance.-For induction of specific immune tolerance to Ak tissues, cell suspensions from thymus or spleen of one-month-old healthy Aki donors were prepared by teasing out in buffered Ringer phosphate solution, washing twice, and resuspending in the buffered solution so that 0U05 ml. of the suspension contained 5 to 7 million cells. This amount of the freshly prepared suspension was injected into the anterior facial vein of newborn C3Hf/PW mice less than 20 hours after birth.
Skin grafts.-Skin grafts were performed according to the method of Billingham and Medawar (1951) at 6 to 8 weeks of age. The grafted skin was from 2-months-old healthy Aki female mice and served as the external indicator of the tolerant state. Only fully tolerant mice, carrying healthy skin grafts were used experimentally.
Histology.-Tissues for histological examination were fixed in Bouin's fluid and stained in haematoxylin and eosin. 84 Detailed results are presented in Tables II to VIII. The salient features of these tables may be summarized as follows. Incidence of spontaneous leukaemia (Table II) Only the Aki strain had a high incidence of spontaneous leukaemia during the fourteen month period of observation. The final figures for the full life span of the low-leukaemic strains may well be rather different. reduced from about 9 months to about 5 months. This effect must be regarded as an acceleration of the leukaemogenic process. The total incidence of the disease in the inoculated group was slightly lower than in the completely untreated group as a result of a higher mortality from non-leukaemic causes in inoculated mice.
A slightly increased incidence of leukaemia was observed in C3Hf/PW and CBA/H mice following injection of Ak leukaemic filtrates at birth.
Thirty-one separate Ak filtrates were used in these experiments but only 8 were associated with leukaemogenic activity in C3Hf/PW and CBA/H mice (Table IV) . Five filtrates each produced leukaemia in 2 mice and in 3 cases the 2 mice came from the same litter. Sixteen of the filtrates used were responsible for the development of early leukaemias in inoculated Aki mice.
(c) Passage A filtrate.-Injection of Passage A filtrate at or soon after birth gave 100 per cent incidence of leukaemia in both C3Hf/Gs and Aki mice as early as 2 to 4 months. This filtrate increased the incidence of leukaemia following injection into newborn C3Hf/PW mice to about 27 per cent the disease developing between 7 and 10 months of age. The development of a potent Ak filtrate (Table V) Filtrates from Ak leukaemic tissues was passed through serial cell-free inoculations into 4 successive generations of newborn Ak mice. In each passage, the first Ak mouse that developed leukaemia was used as donor for the preparation 86 of the next passage-extract. The final filtrate considerably increased the total incidence of the disease and accelerated the average age of onset when inoculated into C3Hf/Gs mice at or soon after birth. The incidence of lymphocytic leukaemias in mice inoculated as adults with cell-free extracts of leukaemic tissues (Table VI ) Cell-free filtrates of leukaemic tissues of Ak mice were not capable of inducing leukaemias in adult C3Hf/Gs or C3Hf/PW mice. Though a high number of Aki mice developed leukaemia following injection at 4 to 8 weeks of age with filtrates of Ak leukaemic tissues, the total incidence and average age of onset were almost the same as in untreated Aki mice. It must, therefore, be assumed that the filtrates had no noticeable effect when injected into adult mice.
Passage A filtrate given to C3Hf/Gs at 4 to 8 weeks of age did produce some leukaemias but not as efficiently as the same filtrate given at or soon after birth.
The incidence of lymphocytic leukaemia in C3Hf/PW mice tolerant to Ak, and inoculated as adults with cell-free extracts of Ak leukaemic tissues ( No leukaemia occurred in C3Hf/PW mice made tolerant to Ak and injected 1 month after birth with cell-free filtrates from Ak leukaemic tissues (Table VIII) . Sixteen of the mice in this group received at least one of the 8 filtrates that was associated with leukaemogenic activity following inoculation into newborn C3Hf/PW or CBA/H mice.
DISCUSSION
The work described here confirms the results obtained by Gross (1958b) and others (Woolley and Small, 1956; Furth et al., 1956; Dulaney et al., 1957; Hays and Beck, 1958; Kassel and Rottino, 1959) .
Cell-free extracts of tissues of Ak mice with spontaneous leukaemia are clearly capable of leukaemogenic activity. In the high-leukaemia Ak strain and in the (AKRXC3Hf)Fl hybrids, there is little or no change in leukaemia incidence but an acceleration of the onset of the disease following inoculation of extracts at birth (Rudali, Duplan and Latarjet, 1957; Law, Dunn and Boyle, 1955) . The leukaemic agent has been shown to be present in young healthy Ak mice (Gross, 1951 (Gross, , 1953 , so that inoculation of leukaemic extracts into these mice must be assumed to increase the quantity of agent already present in the host. Acceleration of leukaemia may thus be explained on a purely quantitative basis. Extracts from normal tissues of low-leukaemic C3H mice failed to be associated with leukaemogenic activity following inoculation into newborn C3H mice (Gross, 1955b) . These mice may, therefore, not carry the leukaemic agent, and leukaemia occurring as a result of inoculation of Ak leukaemic extracts must presumably have been induced by the agent. It is true, however, that the disease occurs spontaneously in low-leukaemic strain mice (Law, 1957) and two cases have been diagnosed in our colony of C3Hf/PW kept under observation for only 14 months. 88 These two cases still have to be explained. It is possible that some of the C3H mice carry the agent, but that our methods are not sensitive enough to demonstrate its presence ? If this is so, does the inoculation of leukaemic filtrate at birth simply accelerate the onset of the disease in mice that would develop it if they lived long enough ? Some agent must be present in C3H mice since Gross claims to have activated it by X-irradiation (Gross, 1958a) . The point at issue is whether this agent is or is not identical to that present in high-leukaemia strains.
Filtrates from Ak leukaemic tissues have been shown to vary considerably in their activity. Many of them were associated with the development of early leukaemia in Ak mice, but only few produced leukaemia in C3Hf/PW mice (Table IV) . Gross developed his potent Passage A filtrate (Gross, 1957b) by selecting an active Ak leukaemic extract and passing it through serial cell-free inoculation of newborn C3Hf/Gs mice. In the work reported here, a potent extract was obtained in a similar way but in a relatively shorter period of time, the extracts being passed through successive generations of newborn Ak mice instead of C3Hf/Gs mice (Table V) . No doubt this procedure must select and concentrate active agent, since dilution of the final potent extract reduces the total incidence and delays the average age of onset of leukaemia in inoculated mice (Gross and Dreyfuss, 1959) .
Subline differences exist in respect to susceptibility to leukaemogenesis by any given extract as was pointed out by Gross (1955a) and Woolley and Small (1957) . In this study, a valid comparison can be made of the response of 2 sublines of C3H mice, both originally obtained from Bittner, since both were injected simultaneously with the same filtrate, Passage A. It is obvious from Table III that the C3Hf/Gs subline is by far the more sensitive.
Only newborn mice were susceptible to the leukaemogenic activity of filtrates prepared from tissues of Ak mice with spontaneous leukaemia. This may be due to:
(1) A state of immunological unresponsiveness;
(2) a concentration effect; (3) factors, other than immunological, inherent to the particular stage of development of the animals at birth.
(1) It has been suggested that immunological tolerance is the reason why only newborn mice are susceptible to an agent recently isolated from a foreign strain (Harris, 1958; Barnes et al., 1959) . In this study, a state of acquired tolerance in C3H mice to transplantation antigens of Ak mice did not appear to give tolerance to the Ak leukaemic agent (Table VIII) . The mice were fully susceptible to grafts of Ak leukaemic cells but not to the leukaemogenic activity of the Ak agent. For the induction of tolerance, normal Ak cells, which according to Gross (1953 Gross ( , 1959 contain the agent, were injected intravenously at birth, and yet no leukaemia developed. Perhaps the quantity of agent in 5 million normal Ak cells is not sufficient for leukaemogenesis, or perhaps the agent is intracellular, antigenically distinct and must be introduced in the free state in newborn animals.
(2) Simple quantitative factors may serve to explain the age susceptibility to the leukaemogenic effect of cell-free filtrates. For any active filtrate, the concentration of agent present in the newborn after inoculation must be relatively far greater than that which can be attained in an adult mouse. Augmentation of " infectivity " presumably occurs as a result of selection of the most active extract 89 after serial passage through successive generations of mice of any one strain. A far greater concentration of active agent can then be achieved following inoculation into suckling or young adult mice. This may explain why acceleration of leukaemia in Ak mice by Ak filtrate can only occur when the filtrate is given at birth, and why, on the other hand, Passage A can accelerate Ak leukaemia when given to older Ak mice or can produce leukaemia after inoculation into young adult C3Hf/Gs mice.
(3) Shubik has pointed out that the response of newborn mice to filtrates should also be viewed as a response of a sensitive biological system to carcinogenesis (Pietra, Spencer and Shubik, 1959) . He reports a high incidence of early malignant lymphomas in a relatively insusceptible strain of mice following the inoculation at birth of a single low dose of chemical carcinogen.
All the leukaemias developing in our inoculated mice were lymphoid with thymus involvement resembling typical spontaneous lymphomas in Ak mice. They were all transplantable to mice of the recipient line, and many were transplantable to both donor and recipient strains. This confirms similar observations made by Furth et al. (1956) and Gross (1958c) . No other tumours, nor tumours characteristic of polyoma virus infection (Stewart et al., 1957) were seen in any of the mice of the present series in contrast to the results of other workers in this field (Stewart, 1955 ; Law et al., 1955 ; Salaman, 1959) . Salaman, for instance, recorded the occurrence of 40 tumours (but no leukaemia) among 15 out of 23 C3Hf/Bi mice inoculated at birth with leukaemic filtrate. However, the filtrates were prepared from leukaemias that had already been transplanted three times by cell graft through AKR mice. Gross has stressed that as far as leukaemogenesis by cell-free extracts is concerned, the source of material should either be a spontaneous leukaemia or one induced with leukaemic extracts rather than a transplanted leukaemia (Gross, 1956 (Gross, , 1958b . Some supporting evidence for this claim was obtained by Kassel and Rottino (1959) who showed that extracts prepared from transplanted AKR leukaemic tissues resulted in the development of parotid tumours, adrenal tumours, osteosarcomas and fibromyxomas but no leukaemia.
It would be pure speculation to attempt, on the basis of the present results, to identify the agent in leukaemic filtrates as a virus or as a genic complex derived from either neoplastic or potentially neoplastic cells. An increase in leukaemia incidence, per se, does not establish the existence of a virus-mediated mechanism. Final identification of the agent must await further investigations of its biological and physicochemical properties. SUMMARY 1. Newborn or adult mice of the low-leukaemic strains C3Hf/PW, C3Hf/Gs, CBA/H, and of the high-leukaemic strain Aki were inoculated intraperitoneally with cell-free extracts prepared from tissues of Ak mice with spontaneous leukaemia, and of C3Hf/Gs mice with leukaemias induced by leukaemic filtrate, Passage A.
2. Ak leukaemic filtrates inoculated into newborn low-leukaemic strain mice resulted in leukaemia in 11-8 per cent of 68 C3Hf/PW mice at 7 to 14 months and 7 per cent of 71 CBA/H mice at 6 to 15 months. No leukaemia occurred when these filtrates were inoculated into 34 adult C3Hf/PW mice or 18 adult C3Hf/Gs mice.
3. Passage A filtrate resulted in 26-7 per cent leukaemias at 7 to 10 months when inoculated into 45 newborn C3Hf/PW mice and 100 per cent leukaemia at 2 to 4 months following inoculation into 87 one-to 14-days-old C3Hf/Gs mice. The same filtrate produced 60 per cent leukaemias when inoculated into 20 oneto 2-months-old C3Hf/Gs mice.
4. Acceleration of the onset of leukaemia to 3 to 6 months occurred in 68 per cent of 75 Ak mice inoculated at birth with Ak leukaemic filtrates but in none of 18 Ak mice inoculated at 1 to 2 months of age. Passage A filtrate accelerated leukaemia in 100 per cent of 15 Ak mice inoculated between 1 and 14 days of age.
5. Transplantation of some of the leukaemias produced in C3H mice revealed some ambivalence: all were transplantable to C3H mice but many were also transplantable to mice of the original donor Ak strain.
6. Increase in potency of an Ak leukaemic filtrate was evident after 4 serial cell-free inoculations of newborn Ak mice. The final filtrate was associated with the development of leukaemia at 3 to 6 months in 68.8 per cent of 16 C3Hf/Gs mice inoculated between 1 and 5 days.
7. No leukaemia developed in 79 C3Hf/PW mice which received at birth an intravenous injection of normal spleen and thymus cells from healthy young adult Ak mice. Fifty-nine of these mice received, in addition, intraperitoneal injections of Ak leukaemic filtrate at 4 to 8 weeks of age. All the mice in this group were fully tolerant of Ak skin grafts.
8. Only lymphocytic leukaemias or lymphoid tumours confined to the thymus were seen in mice of the present series. No other tumours such as those described by other workers in this field have appeared.
